Tenofovir Alafenamide Tablets IP 25 MG – Next-Gen Protection for HIV & HBV.
ZEFOTEN AS 25 Tablets: The composition of Tenofovir Alafenamide 25 mg is a next-generation nucleotide reverse transcriptase inhibitor (NtRTI) used in the management of HIV-1 infection and chronic Hepatitis B virus (HBV) infection. By blocking viral replication, it lowers the viral load, slows disease progression, and preserves immune function. Compared to earlier tenofovir formulations, TAF delivers vigorous antiviral activity at a much lower dose, significantly minimising the risks of renal impairment and bone density loss, making it a safer and more effective long-term therapy option.
Recommended By Specialists:
✅General Physician : It is prefer to treat the disease associated for long-term antiviral and antiretroviral therapy in routine care settings.
✅HIV Specialists: It is prefer to treat the disease associated for adults and adolescents requiring ART regimens for HIV-1.
✅Hepatologists and gastroenterologists: It is preferable to treat the disease associated with chronic hepatitis B infection and prevent HBV complications.
Key benefits of Tenofovir Alafenamide Tablets IP 25 MG – ZEFOTEN AS 25 Tablets:
✅Strong Dual Antiviral Effect – Provides effective suppression of both HIV-1 and HBV replication.
✅Enhanced Safety & Tolerability – Lower systemic exposure than Tenofovir Disoproxil Fumarate (TDF), reducing risks of kidney and bone toxicity.
✅Simple Once-Daily Regimen: Improves treatment adherence and long-term therapeutic success.
Indications:
✅Chronic Hepatitis B Infection
✅HIV-1 Infection Management (as part of combination therapy)
✅HBV Reactivation Prophylaxis
✅Safer Antiviral Option in Patients with Renal Concerns
✅Core Component of Antiretroviral Therapy (ART) Regimens










